TTrialPathMatch Me to Trials
← Back to trials
RecruitingCOPD (Chronic Obstructive Pulmonary Disease)Cancer Lung ScreeningSmoking Cigarette

University of Michigan COPD Identification Through Lung Cancer Screening Cohort Study - MAP2

Eligible age

50–80 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to obtain new knowledge regarding screening for COPD. This study will use a participant's cancer screening CT scans performed as part of routine health care among current and former smokers at risk for COPD to identify participants who have had a spirometry or will have a spirometry test as part of the study to verify COPD status.

Sponsor: University of Michigan

You may qualify if…

  • ✓ Eligible for lung cancer screening by USPSTF 2021 criteria including age 50-80 years and currently or formerly smoking with at last 20 pack-years of smoking history at the time of consent.
  • ✓ Willingness to participate in an observational clinical trial and to be contacted about future ancillary studies that could include interventional clinical trials.
  • ✓ Ability to tolerate study procedures.
  • ✓ Ability to provide informed consent.
  • ✓ Clinical Lung Cancer Screening CT performed at the University of Michigan within the last year
  • ✓ Meets one of the three following criteria:
  • ✓ 1. Prior Diagnosis of COPD in the EMR
  • ✓ 2. Prior pulmonary function meeting criteria for COPD (FEV1/FVC ≤ 0.70) or

You may not qualify if…

  • ✕ The presence of a respiratory condition other than COPD or asthma, or of a comorbid condition that in the judgment of the investigator may be the principal cause of respiratory symptoms (e.g. dyspnea or decreased exercise tolerance).
  • ✕ Severe asthma, which is defined as any of the following:
  • ✕ Current (i.e. at the time of the visit) GINA Step 4 or higher therapy (medium dose ICS/LABA or high dose ICS or add-on LAMA; Medium dose = \>250 fluticasone propionate =100 fluticasone furoate, \>200 beclomethasone, \>400 budesonide, \>220 mometasone). The investigators will accept low-dose ICS/LABA or medium dose ICS.
  • ✕ or 3 or more unscheduled healthcare visits (provider/urgent care/ER) for asthma in the past 12 months or One asthma hospitalization in the past 12 months
  • ✕ Concurrent participation in a therapeutic trial where treatment is blinded.
  • ✕ Active pregnancy. Documentation of birth control will be required for pre-menopausal women.
  • ✕ Cognitive dysfunction that prevents the participant from completing study procedures.
  • ✕ BMI \> 35 kg/m2 at baseline, due to the effects of body weight on CT scan quality.

Where it's recruiting

Michigan

Ann Arbor

Source: ClinicalTrials.gov · NCT07482475 · last updated 2026-03-25

University of Michigan COPD Identification Through Lung Cancer Screeni · TrialPath